461 related articles for article (PubMed ID: 35264438)
21. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
22. The Actual Status of Hospitals as COVID-19 Vaccination Clinics in China and Safety Monitoring of Inactivated Vaccine: A Cross-Sectional Study.
Huang J; Zhang MQ; Huang MZ; Lin GM
Disaster Med Public Health Prep; 2022 Aug; 17():e256. PubMed ID: 36017705
[TBL] [Abstract][Full Text] [Related]
23. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
Joudi M; Moradi Binabaj M; Porouhan P; PeyroShabany B; Tabasi M; Fazilat-Panah D; Khajeh M; Mehrabian A; Dehghani M; Welsh JS; Keykhosravi B; Akbari Yazdi A; Ariamanesh M; Ghasemi A; Ferns G; Javadinia SA
Front Endocrinol (Lausanne); 2022; 13():798975. PubMed ID: 35299966
[TBL] [Abstract][Full Text] [Related]
24. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
25. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
[TBL] [Abstract][Full Text] [Related]
26. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
28. The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
Al Kaabi N; Oulhaj A; Al Hosani FI; Al Mazrouei S; Najim O; Hussein SE; Abdalla JS; Fasihuddin MS; Hassan AA; Elghazali G; Al Rumaithi A; Al Azazi J; Weber S; Beiram R; Parekh KA; Sheek-Hussein M; Yang Y; Xiaoming Y; Quliang J; Eltantawy I; Mahmoud S; Koshy A; Xiao P; Ganesan S; Elamin W; Zaher W
Sci Rep; 2022 Jan; 12(1):490. PubMed ID: 35017530
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country.
Macchia A; Ferrante D; Angeleri P; Biscayart C; Mariani J; Esteban S; Tablado MR; de Quirós FGB
JAMA Netw Open; 2021 Oct; 4(10):e2130800. PubMed ID: 34714342
[TBL] [Abstract][Full Text] [Related]
30. Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F; Giannarelli D; Fabbri A; Virtuoso A; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Panichi V; Topini G; Silvestri MA; Ruggeri EM
Cancer Immunol Immunother; 2023 Oct; 72(10):3217-3228. PubMed ID: 37428196
[TBL] [Abstract][Full Text] [Related]
31. Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis.
Leppelmann KS; Mooradian MJ; Ganguli S; Uppot RN; Yamada K; Irani Z; Wehrenberg-Klee EP; Zubiri L; Reynolds KL; Arellano RS; Hirsch JA; Sullivan RJ; Fintelmann FJ
J Vasc Interv Radiol; 2021 Feb; 32(2):187-195. PubMed ID: 33353814
[TBL] [Abstract][Full Text] [Related]
32. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
33. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
34. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
35. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
[TBL] [Abstract][Full Text] [Related]
36. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors.
Zou H; Ge Y; Chen W; Yao D; Oi Lam Ung C; Lai Y; Hu H
Int Immunopharmacol; 2024 May; 132():111947. PubMed ID: 38552296
[TBL] [Abstract][Full Text] [Related]
37. Altered T-cell receptor β repertoire in adults with SARS CoV-2 inactivated vaccine of BBIBP-CorV.
Quan Z; Qi A; Ma S; Li Y; Chen H; Yu X; Dong T; Li K; Qiu Y
Mol Immunol; 2023 Oct; 162():54-63. PubMed ID: 37647774
[TBL] [Abstract][Full Text] [Related]
38. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
39. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
40. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
